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Abstract
Half of all cancer patients receive radiotherapy, which makes a substantial contribution to their long-term dis-
ease control/cure. There are significant inter-patient differences in response, both in terms of efficacy and toxic-
ity (frequently delayed onset) which are difficult to predict. With the introduction of technological
improvements (e.g. stereotactic body radiotherapy and proton therapy) and development of combination thera-
pies (e.g. radiotherapy and immune checkpoint inhibition), predictive biomarkers are needed even more. Whilst
genomic studies have contributed significantly to predictions of response to anticancer therapy, there is no doubt
that more information can be gathered from patient tissue samples. Patients are willing to donate their tissues
to biobanks and wish them to be used as widely as possible for high-quality research. We report here a survey of
the current practices in the UK from several groups collecting material from patients in radiotherapy trials and
have identified barriers to collecting and sharing data and samples. We believe the current situation represents a
significant missed opportunity to improve the personalisation of radiotherapy. We propose a greater involvement
of patients and/or their advocates, a standardisation of the patient information leaflet, consent form content and
data set, with easy linkage to clinical data, which would facilitate widespread sample and data discovery and
availability to other researchers. The greater sharing of data and samples, nationally and internationally, would
facilitate robust multicentre studies and avoid duplication of effort.
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Introduction
In high-income countries, 50% of all cancer patients
will receive radiotherapy [1] at some point in their
treatment pathway, contributing to the curative treat-
ment of 30–40% of patients [2]. Globally, the number
of patients requiring radiotherapy increases year on
year [3]. Radiotherapy (often with concurrent chemo-
therapy) is now the primary standard of care treatment
for many cancers to facilitate organ preservation
(e.g. head and neck, cervical, and anal cancers) with
high rates of cure [4,5]. Radiotherapy remains an alter-
native to surgery across a number of situations
(e.g. prostate and bladder cancers [6,7]) and as adju-
vant therapy in, for example, breast cancer [8]. Techni-
cal refinements are facilitating hypo-fractionated
treatments leading ultimately to stereotactic body
radiotherapy [9] with patients receiving curative doses
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of radiotherapy in only a few treatments. Equally,
novel immunotherapy combinations (e.g. non-small
cell lung cancer [10]) continue to improve patient out-
comes and broaden radiotherapy indications.
However, not all patients are cured and radiotherapy
can be associated with serious and delayed sequelae,
hence the potential of personalised treatment to
improve both treatment efficacy and long-term quality
of life. Progress is slow – for example, although the
positive influence of tumour human papillomavirus
(HPV) involvement on outcomes after (chemo)radio-
therapy for head and neck cancer was first described a
decade ago [11], trials of dose modulation based on
this biomarker are yet to report [12]. Other studies uti-
lise more general biomarkers of risk [13] as opposed
to specific predictors of radiotherapy effect/toxicity.
Preclinical studies have identified multiple determi-
nants of both radio-sensitivity and radio-resistance that
have the potential to be used as predictive biomarkers
for both response and undesirable sequelae. Searchable
databases of genomic and transcriptomic information
have contributed significantly to biomarker identifica-
tion, notably The Cancer Genome Atlas [14]. The col-
lection of blood samples for radiogenomics has
accelerated recently [15]. However, to fully translate
the accumulating knowledge into useable biomarkers
for precision oncology, the biobanking of properly
curated tumour and normal tissue samples, surplus to
diagnostic/clinical need, is essential along with appro-
priate (anonymised) clinical data.
Tissue samples may be diagnostic biopsies, excess
tissue from surgery, or collected as part of a clinical
trial where participation mandates blood and/or tissue
collection. Paired pre- and post-radiotherapy biopsies
are extremely valuable for ‘proof of mechanism’ stud-
ies but particularly challenging to collect as the patient
must consent to repeated invasive procedures. How-
ever, there are clinical indications for repeat biopsies
post-treatment such as biopsy or removal of the pri-
mary tumour and secondary recurrence or, for exam-
ple, sentinel lymph node biopsy in patients undergoing
radiotherapy for breast cancer [16–18]. Whilst primary
tumour samples can be difficult to obtain, blood sam-
pling provides opportunities for ‘liquid biopsy’ of both
circulating cell-free tumour DNA (ctDNA), circulating
tumour cells (CTCs), and tumour extracellular vesicles
pre- and post-radiotherapy [19]. These can be collected
serially, avoiding the complications of invasive biop-
sies especially in hard-to-reach or high-risk tissues
such as lung and brain, potentially yielding predictive
biomarkers of radiotherapy response.
Patients want their material put to good use with the
ultimate goal of improving the outcomes of patients in
the future [20,21]. Quoting our patient representative,
the key message here is that ‘Biobanks should not be
Safety Deposit boxes accessed by the privileged few
but more like open access accounts with stakeholders
and others having easy access to deposit and with-
draw’ [22].
Whilst clinical trials may include biobanking of
patient material, these studies are usually small and col-
lected for a specific purpose, limiting access. Where
biobanking is part of a phase I trial of a novel drug, the
availability of samples is less likely to be a major issue
but, for a widely used treatment modality like radiother-
apy, the desirability of sharing the material is increased.
A UK survey of pathology departments identified
inconsistency in tissue release for clinical trials, with
lack of time and/or resources cited as the biggest bar-
riers [23]. This, together with the lack of a standardised
approach to consent, collection, handling, and storage,
along with an often variable set of associated patient/
clinical data, presents challenges for samples to be shared/
pooled in order to obtain meaningful data. The UK
National Cancer Research Institute (NCRI) recognised
this and, with the goal of improving biobanking in gen-
eral, established the Confederation of Cancer Biobanks
[24] in 2006, and incorporated it into the NCRI Cellular
Molecular Pathology (CMPath) initiative in 2016; the
objective is to share best practice, to improve the coordi-
nation between existing collections, and to raise aware-
ness of existing collections. CMPath worked towards
improving and standardising sample collection and repor-
ting by devising a freely available Biobanking Sample
Quality Improvement Tool [25] highlighted by the need
for sample and data standardisation, especially for bio-
marker studies [26,27].
In radiotherapy biobanking, the GENEPI-ENTB2
project (GENEtic pathways for the Prediction of the
effect of Irradiation-European normal and tumour tis-
sue bank and database) sought to address shortfalls by
establishing a database of patient treatment and out-
come information, linked to a biobank of tissue sam-
ples [28]. This was achieved through the coordination
of multiple small biobanks throughout the EU into a
‘virtual EU tissue bank’. The GENEPI-ENTB2 project
documented 12,120 samples from 5,844 radiotherapy
patients and 960 healthy volunteers [29]. The final
report (2011) [30] highlighted challenges with the IT
system and resources required for its management but
provided a framework for future biobanking [29,31].
Learning from the experience of GENEPI-ENTB2
and CMPath, we sought to review the current UK
landscape of radiotherapy-related biobanking and to
propose a system of measures that might enable the
effective collection, curation, and sharing of this
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valuable resource given by patients altruistically to
hopefully enable improvements in patient outcomes.
Public and patient involvement in biobanking
Patient material is a valuable resource, patients consent
willingly, but their role in biobanking has histori-
cally been passive. Healthcare institutes are beginning
to recognise patients as actively involved consumers
or collaborators in research [32,33]. Nevertheless,
patients still have no say over the scientific or clinical
application of samples they have gifted. Patients have
a right to know that their samples are valued, stored,
and utilised appropriately, and that what will happen
to them at the end of their shelf-life (including dis-
posal) is clearly stated.
Some well-resourced UK biobanks, such as the
charity-funded Breast Cancer Now Tissue Bank [34];
Blood Cancer UK CellBank [35]; Pancreatic Cancer
Research Fund Tissue Bank [36]; and the part govern-
ment, part charity-funded Wales Cancer Bank [37],
involve patients in governance of the repository and
tissue access committees and some include patients in
the overall management of the biobank such that they
know what happens to their samples and their contri-
bution to research [33]. If we acknowledge that
patients should be fully informed and engaged when
consenting to donate, then this also applies when they
are asked to comment/decide on the use of such sam-
ples [32]. Patient representatives can learn how to nav-
igate the esoteric terminology and concepts through
the Science for Advocates course developed by the
Independent Cancer Patients’ Voice [38].
Large multicentre radiogenomics studies involving
close co-operation across many countries have been
successfully undertaken recently. REQUITE (Validating
pREdictive models and biomarkers of radiotherapy tox-
icity to reduce side-effects and improve QUalITy-of-
lifE in cancer survivors) has its own associated biobank
of centrally held samples, collected regularly from local
centres [39]. The REQUITE project has patient repre-
sentatives on both its management and publication com-
mittees. Patient involvement with such large projects is
internationally acknowledged and implemented but sel-
dom reported in publications. However, many smaller
collections lack sufficient transparency to ensure that
sample access can extend beyond the immediate clinical
trial group to prevent monopolisation of the resources.
The question of how applications for sample access are
assessed and by whom is still an issue.
The UK radiotherapy biobanking landscape
To understand the current situation with respect to the
collection of, and access to, biological samples in radio-
therapy research in the UK, we devised a questionnaire
that was sent to the 55 members of the NCRI Clinical
and Translational Radiotherapy Research Working
Groups (CTRad), requesting information regarding
whether they collected tissue samples and, if so, the
type of tissue samples, logistical infrastructure, current
permissions regarding the sharing of tissue samples,
and identifiable barriers to the storage and/or sharing of
tissue samples (supplementary material, Section S1).
A total of 12 responses were obtained with 8 respon-
ders collecting tissues and 4 not collecting. The small
sample size prohibited formal statistical analysis but
provided a useful insight into the current landscape.
Only two respondents collected tissue samples for
general use with the remainder stating that consent was
only obtained for sample use in the specified project,
and samples could not be shared. However, most respon-
dents would have been happy to share samples and
data if access was appropriately peer reviewed and all
would be happy to collect into a central biobank using a
generic consent form and collection of a minimum data
set if templates had been available. The majority of tis-
sue samples and related data were stored in a study-
specific database or a clinical trials research unit that
were either part of a national, institutional, or individual
biobank (Figure 1A,B). One barrier to sharing was
discrepancies in the level of detail given regarding the
future use or sharing of collected samples on the consent
form. Detail ranged from ‘donating tissue for future
research’ to specifying a permitted location, team, and
funding for future research (Figure 1C). There was
also variation in the demographic/clinical data collected
(Figure 1D).
Numerous tumour sites were represented amongst
samples collected, with the highest number of responses
for samples of the prostate, pancreas, lung, and breast
(Figure 2A) largely reflecting the clinical use of radio-
therapy [40]. Samples were also collected at various
time points in the treatment pathway (Figure 2B).
Regarding administrative support for biobanking,
the most common was a data manager, followed by a
biobank manager and quality assurance manager. The
most common barrier to collecting, processing, and
banking of tissue was a lack of facilities followed by a
lack of biobanking support and lack of sample track-
ing software. These responses echo attitudes and prac-
tices uncovered by a related survey [23]. A second
survey sent to the entire CTRad membership 2 years
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Figure 1. Response to CTRad survey regarding collection of samples and data. (A) Where samples are collected, (B) how the data relating to
the samples are stored, (C) restrictions on consent form (animal experimentation may not be permitted at all or only with restrictions, and
(D) variability in the demographic and clinical data collected. Data are from 12 respondents out of 55 solicited. *Aetiology: relevant
aetiological data (e.g. smoking history, HPV, body mass index, etc). MA, medical achiever; OS, overall survival; PFS, progression-free survival.
Figure 2. Responses from CTRad questionnaire regarding tissue collection and storage matrix. (A) Tumour types collected and (B) nature
of samples taken. Data are from 12 respondents out of 55 solicited.
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later elicited 57 responses of which 36 groups had the
opportunity to collect patient material. Although only
six answered all the questions, the data reflected the
previous survey in that collections were generally as
part of a clinical trial and those who did not collect
cited lack of infrastructure or funding as the reason.
Recognising the low response rate to our survey, we
contacted the chief investigators of all (68) studies
held on the NIHR Clinical Research Network (CRN)
Portfolio of clinical trials (March 2019) involving
radiotherapy and/or observational/biomarker studies [41].
Responses were obtained from the investigators of
57/68 (84%) radiotherapy studies. Of these, 37 trials
(65%) included translational components, with 35 col-
lecting biological material. Twenty-five studies incor-
porated biobanking funding within the main study
grant; the other 12 entailed separate, sequential appli-
cations (Figure 3A). The vast majority (35/37) were
undertaking exploratory work – only 2 used collected
biological material as stratification factors for the trial.
Figure 3. Status of tissue collection activity in recent UK radiotherapy studies. (A) Data from 57 (of 68 surveyed) UK radiotherapy stud-
ies. (B) Funding source for tissue collection for 35 studies that report biobanking biological material. (C) Integrating a sample collection
[formalin-fixed, paraffin-embedded (FFPE) baseline and relapse samples] plus serial plasma in high-risk cases for cell-free DNA and CTCs
within the UK Anal Cancer Platform trial PLATO (PLATO; PersonaLising Anal cancer radioTherapy dOse) maximises translational opportu-
nities [42]. Patients were also co-enrolled into RAPPER, obtaining a whole blood sample for genome-wide association studies into the
radiogenomics of toxicity [46]. Future radiomic and gut microbiome studies are in development.
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These components were charity funded in 23 of
37 cases, many (14) by the Cancer Research
UK. Six were funded by commercial (pharmaceutical
industry) partners and three supported by the local
academic institution. This distribution of funding
sources concurs with responses to the initial ques-
tionnaire, suggesting most were funded by national
or international charities (Figure 3B).
One example is the anal cancer platform PLATO
(PersonaLising Anal cancer radioTherapy dOse;
ISRCTN88455282) [42] funded by the Cancer Research
UK and Stand Up to Cancer. Chemoradiotherapy repre-
sents standard of care in anal squamous cell carcinomas
[5] where it is curative in this HPV-associated cancer [43].
Key translational questions include those around HPV
transformation, radiotherapy sensitivity/response, and pre-
diction of radiotherapy toxicity [44]. The integrated sample
collection and biomarker analysis project (Figure 3C)
funded in parallel includes a serial plasma collection,
addressing these questions and more. Patients enrolled in
PLATO are also encouraged to provide samples within the
RAPPER study (Radiogenomics: Assessment of Polymor-
phisms for Predicting the Effects of Radiotherapy), investi-
gating genomic predictors of toxicity [45,46]. With
>10,000 patients, RAPPER is the largest radiogenomics
resource in the world.
These data are in many ways encouraging. Nearly
two-thirds of current UK clinical trials involving radio-
therapy include collection/analysis of biological sam-
ples, supported by a variety of funders. Mostly, the
translational work is exploratory; we are not yet in the
era of biologically stratified radiotherapy studies. In
addition, it remains unclear just how accessible this
material, together with the important clinical demo-
graphic and treatment details, might be to future
researchers. In registering a UK clinical trial, the Inte-
grated Research Application System [47] specifically
asks what will happen to tissue samples at the end of a
study, providing the option to deposit samples within a
biobank and using this option would ensure tissue sam-
ples can be made available. Internationally, one such
exemplar is the French glioblastoma biobank [48].
Future perspectives
Material is clearly being collected from patients under-
going radiotherapy across a number of clinical trials
but samples are neither as visible nor as accessible as
they might be, use diverse consent forms, and collect
different data points. With visibility and appropriate
consent, they could be used by other researchers to
improve radiotherapy (see the checklist in supplemen-
tary material, Section S2), for example, biomarkers pre-
dictive of (progression-free) survival following
radiotherapy [49]. Advances in understanding the role
played by DNA repair mechanisms in the cellular
response to ionising radiation [50], and how the tumour
micro-environment and immune response modulate
outcomes [51], present a plethora of candidate bio-
markers for translational research aiming to optimise
radiotherapy treatments. The recent development of rel-
atively non-invasive liquid biopsies (ctDNA and CTCs)
means there is a greater potential to collect material for
research into the molecular basis of radiosensitivity and
toxicity, as exemplified recently by analyses of ctDNA
collected from oesophageal cancer patients [52]. How-
ever, this can only be optimally exploited if the mate-
rial is made available to diverse groups. The use of
such tests has already impacted clinical decision-
making in the non-radiotherapy setting such as the plas-
maMATCH trial, which successfully used ctDNA to
identify breast cancer patient subgroups who were sen-
sitive to targeted therapies [53].
To address the lack of standardisation across con-
sent forms, and associated discrepancies in permis-
sion for sharing tissue samples between studies, a
standardised consent form may be desirable (supple-
mentary material, Table S1). This was unanimously
supported by respondents to the initial questionnaire,
provided that sufficient support would be made avail-
able, and is an objective of CMPath. Such consent
forms must consider the patients’ perspective, and rec-
ognise that cultural and spiritual backgrounds may
have a bearing in this regard [54,55]. One important
issue concerns the use of samples by pharmaceutical
companies and for-profit researchers in discovery/
validation programmes to avoid exploitation and pro-
mote accountability and recompense [56]. Involvement
of patients as collaborators through Public Patient
Involvement improves donor retention and recruit-
ment. In addition, engagement with scientists improves
the understanding of the importance and value of these
gifted samples, and the expectations patients have on
the output of the research.
Similarly, collection of a standardised set of clinical
data (Table 1) would also facilitate sharing of sample
collections and the acquisition of large numbers of
samples pooled from several small studies to generate
meaningful data. One issue here is the need for
standardised terminology when describing available
samples and the metadata associated with a sample.
The Minimum Information about Biobank Data Shar-
ing (MIABIS) approach provides a route to allow sam-
ples to be identified at the individual sample level and
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identification of similar samples across biobanks and
networks [57]. As an extension of this core data set,
consented access to extended medical information of
participants would allow future enrichment of any ban-
ked tissue samples, and this data use is largely accepted
by the public in the UK. The Health Data Research UK
(HDR-UK) provides a framework for acquiring con-
sented access to medical information, providing secure
data curation, and interoperable standards for data han-
dling [58]. Similar activities such as ‘All of Us’ allow
curated large-scale secure access to health data [59].
Integrating these data through ‘Research Data Hubs’
then means that specific large-scale data sets can be cre-
ated and analysed in a secure environment with appro-
priate involvement of patient groups [60].
Virtual tissue banks that allow potential researchers
to locate and request the use of specific samples exist,
notably the UK Prostate Cancer Sample Collection
Database [61]. Attached to each sample collection are
data on the type of sample, location, and contact
information for requesting use, for example, for the
ProtecT (Prostate Testing for Cancer and Treatment)
study [62]. Virtual tissue banks based on sample
databases could act as models for a potential CTRad
database. The UK Clinical Research Collaboration
Tissue Directory (UKCRCTD) [63,64] serves as an
online centralised register of relevant tissue samples
in the UK, allowing researchers to locate specific sam-
ples, with researchers then contacting individual banks
directly to access samples. Similarly, BBMRI-ERIC
[65] provides a European and also international data-
base that links national registers such as UKCRCTD to
their national counterparts [66], with similar resources
present in the US and Canada [67]. This provides
greater access to potentially rare samples and cohorts,
but also harmonisation of processes. A standardised
ontology for biobanks has been derived through
BBMRI ERIC [68], and the MIABIS initiative [69]
describes a hierarchical approach to allow banks, sam-
ples, and data to be described, providing interoperability
across banks by incorporating accepted codes (e.g. the
systemised nomenclature of medicine [SNOMED])
where appropriate. Despite these initiatives, many UK
cancer biobanks still lack visibility, presenting chal-
lenges for researchers in identifying available samples
and how these may be accessed [70] (see the checklist
in supplementary material, Section S2).
Clear information on how biobanks indicate sample
access and usage, and how applications for tissue are
assessed, is needed. Standardised terms of access that
provide a framework for both public and researchers
to understand how samples and data can be accessed
Table 1. Recommended data set for biobanking.
Unique identifier (e.g. collection number with abbreviation for hospital and patient’s initials)
NHS number (to allow future linkage subject to appropriate data governance)
Consent details Consent form number, date of consent, name of person who took it
Consent coverage: general/specific project, consent to genetic (DNA) analysis
Consent opt-outs, e.g. no commercial use
Consent active/withdrawn
Lab number (unique identifier for anonymisation)
Demographics Diagnosis (including stage/grade, if [when] known) and date of diagnosis
Age at diagnosis
Sex
Religious or moral status
Sample details Tissue collection date
Sample site (whole blood/lymphocytes/tumour/lymph node/adjacent normal tissue, etc)
Sample description note (e.g. taken  h after treatment)
Sample type (fresh/snap frozen/cryopreserved/FFPE or derivative sample, e.g. normal/tumour DNA)
Storage location and number of aliquots if relevant
Available for loan
Histology sample number
Treatment details Prior therapy and when given, if known
Post sample therapy planned, if known
Radiotherapy modality, dose, fractionation, and treatment volumes
Additional treatment Chemotherapy/endocrine therapy/targeted therapy/immunotherapy details
Outcomes Date of first recurrence (if/when known)
Date of death (when known and cause of death)
QOL/patient-reported outcomes (including late effects)
FFPE, formalin-fixed paraffin-embedded tissue; QOL, quality of life.
9Radiotherapy biobanking: challenges and aspirations
© 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society
of Great Britain and Ireland and John Wiley & Sons Ltd.
J Pathol Clin Res 2022; 8: 3–13
have been provided by the UK NCRI and other large
organisations [71,72]. Many tissue banks employ this pro-
cess with access policies built around the process of
applying for tissue. These focus on the eligibility to apply,
the application process itself, the review of the applica-
tion, who will be involved with the review of applica-
tions, the terms and conditions of access, and how the
process is governed. Individual access policies for banks
should be developed with the support of patient groups
who should form an integral part of the access committee.
How do biobanks indicate access and usage for the
informed patient and public at large? One possibility
would be a dashboard system on their website dis-
playing metrics such as number of samples in, number
of access applications made, and the number of sam-
ples released to demonstrate that samples and data are
being used [20,21]. Transparency of access is an issue
but, with centralised resources such as those provided
by the Medical Research Council’s Regulatory Support
Centre [73], the use of templates describing access
terms is becoming more common, with Research Tissue
Banks providing these for applicants [72]. The applica-
tion process for tissue can often be seen as opaque, and
there is no unified standard for what constitutes an
access committee. As a key principle, donor or lay
input to evaluation of any application for tissue should
be valued as equal to those of the scientists running the
tissue bank. This would provide donors in particular,
but also potential applicants from the translational
radiotherapy research community, with the assurance
that tissue banks are not static collections, but dynamic
structures with a specific unified aim of distributing
samples and improving patient care.
Recommendations for improvement
While good progress has been made in biobanking,
there is still room for improvement in the radiotherapy
field. Our data from the UK demonstrate a significant
missed opportunity, given the number of patients
receiving radiotherapy within clinical trials. Importantly,
many biological samples and data sets potentially avail-
able (from clinical trials) will have broader relevance to
the research community than the limited primary out-
come measures might involve. Here, we champion
some aspirational challenges for what could be done to
achieve these aims for radiotherapy biobanking:
1. Due regard for the feelings, wishes, and rights of
patients and participants related to: (i) transparency
and rigor regarding access and research project
approval; (ii) publications that acknowledge their
anonymous contribution; (iii) generic consent forms
and patient information leaflets that are easily under-
standable by patients (see supplementary material,
Table S1 and Section S3); (iv) appropriate consent,
curation, and storage to facilitate sharing of samples
and data with the wider scientific community when
the project is complete; and (v) the use of cost
recovery from both academic and commercial users
based on standardised tariffs for samples and data to
support the long-term operation of the biobank.
2. Standard sample collection pathways. Quality guide-
lines and standards exist for biobanking [27] (see
also supplementary material, Table S2), but do not
seem to be adopted universally by those banks that
are not required to follow these regulations. National
and international guidelines have also been intro-
duced and guidance provided by, for example,
BBMRI-ERIC [64], providing frameworks that even
small tissue banks can utilise. Additional profes-
sional standards for biobanking have been introduced
such as ISO21899:2020 and ISBER Best Practice
Guidance [74,75], although given the constraints
placed on funding, these standards may be outside
the budgets of many small biobanks. Stakeholders
must overcome the challenges of local, regional, and
national legislation, and come together to agree a
universal standard for radiotherapy biobanking.
3. To facilitate sample discovery, standard checklists
for applicants should be visible on biobank websites
(see supplementary material, Section S2). These
should detail sample types, who can access these,
how (and by whom) applications are assessed, and if
there are cost recovery mechanisms [70]. In this
respect, use of centralised registries such as the
UKCRC platform or the MIABIS ontology provides
a way of biobanks being identified and utilised.
4. Sharing resources through virtual biobanks. The
NCRI Prostate Cancer Initiative mentioned earlier,
or the model implemented by SEARCHBreast, pro-
vides suitable templates [76]. In these examples, tis-
sues remain at the originating laboratory but are
listed on a secure searchable online database where
researchers can find, share, or upload materials. With
researchers placing increased demands on biobanks,
in terms of the range and type of tissues and data
being requested, one of the biggest challenges faced,
particularly by smaller biobanks, is operational cost.
Most biobanks are poorly resourced and often strug-
gle to cover their costs. Funders may consider cost-
sharing models whereby funding larger centralised
facilities may provide economies of scale. Similarly,
virtual biobanks offer a way of reducing, although
not completely eliminating, such costs. In this
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respect, funders should consider making a condition
of funding the improved visibility of biobanks.
5. Informatics allowing tissue to be linked to patient data
represents a long-term goal to identify how biomarkers
are related to patient therapies and outcomes. The HDR-
UK [77] has provided a platform for health records and
biomarker data to take place based on a series of specific
tasks that allows for curated data analysis.
Summary
To conclude, we champion:
• Patient involvement from the outset, facilitated by
generic consent forms which are easily understand-
able by lay persons
• Widespread sample discoverability and availability
(no ‘ownership’; collegiality, considering patient
wishes)
• Easy linkage to clinical data
• Sharing data (avoiding duplication of effort)
• Standard sample collection pathways
And appeal to funding bodies to prioritise these efforts.
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